Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla")announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single–patient–use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).

This milestone builds on the recent Abbreviated New Drug Approval (ANDA) by United States Food & Drugs Administration (USFDA) obtained by its partner, Orbicular, for Liraglutide Injection(generic Saxenda®). Cipla will lead the product's marketing and distribution, enabling broad access and reliable availability for patients. The company is set to commence the launch on an immediate basis.

Liraglutide Injection is a complex injectable peptide delivered through a multidose injector pen drug–device combination. It is indicated as an adjunct to a reduced–calorie diet and increased physical activity for chronic weight management in patients meeting defined clinical criteria.

Commenting on the launch, Achin Gupta, Global CEO & MD Designate, Cipla, said, "This development represents a key milestone in our peptide portfolio and strengthens our differentiated U.S. offering. We remain focused on expanding access to high–quality, affordable medicines at scale, supported by disciplined execution and collaboration."

Marc Falkin, CEO, Cipla North America, added: "We appreciate Orbicular's work in achieving FDA approval, which enables our immediate U.S. launch. With Cipla's strong commercial infrastructure and deep channel relationships, we are positioned to drive broad availability for customers and patients. This milestone strengthens Cipla's position as one of the few companies offering generic versions of both Victoza® and Saxenda® in the U.S."

GLP–1 receptor agonists have emerged as one of the fastest–growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.

According to IQVIA MAT December 2025, the total addressable market opportunity for GLP–1 therapies in weight management in the U.S. was approximately USD 127 million.